Email Alert | RSS    帮助

中国防痨杂志 ›› 2014, Vol. 36 ›› Issue (11): 936-940.doi: 10.3969/j.issn.1000-6621.2014.11.003

• 论著 • 上一篇    下一篇

化疗联合超声电导经皮透药治疗复治空洞性肺结核的疗效评价

毛晓辉 王龙智 蔡曙波 曹思哲 王勃 吴璇 马庭喜 徐纾 党丽云   

  1. 710061 西安市结核病胸部肿瘤医院内四科
  • 收稿日期:2013-11-02 出版日期:2014-11-10 发布日期:2014-12-05
  • 通信作者: 党丽云 E-mail:mxh13991972590@163.com

Clinical research of chemotherapy combined with ultrasound-guided percutaneous conductivity in the treatment of pulmonary tuberculosis

MAO Xiao-hui,WANG Long-zhi,CAI Shu-bo,CAO Si-zhe,WANG Bo,WU Xuan,MA Ting-xi,XU Shu,DANG Li-yun   

  1. The 4th Department of Medicine, Xi’an Tuberculosis and Thoracic Tumor Hospital, Xi’an 710061, China
  • Received:2013-11-02 Online:2014-11-10 Published:2014-12-05
  • Contact: DANG Li-yun E-mail:mxh13991972590@163.com

摘要: 目的 探讨超声电导经皮透药治疗复治空洞性肺结核的临床疗效。方法 选择西安市结核病胸部肿瘤医院2011年12月至2012年8月,经痰涂片或痰结核分枝杆菌培养确诊为复治继发性涂阳肺结核且合并空洞者183例,按照完全随机法(抽签法)分为化疗联合超声电导组(92例)、单纯化疗组(91例),两组化疗方案均为2HRZES/6HRE,超声电导组在全身化疗的基础上加用超声电导经皮透药治疗(采用超声电导仪及超声电导凝胶贴片进行药物靶位透入,凝胶贴片含有异烟肼注射液0.1 g),观察治疗后1、3、6个月3个时间点各组患者的症状改善情况、痰菌阴转率、结核病灶治疗有效率、结核空洞治疗有效率、并发症及不良反应。结果 超声电导组2例患者因经济原因未完成疗程退组,单纯化疗组1例患者因出现严重肝损伤退组,共计3例患者观察期未满1个月。超声电导组治疗后1、3和6个月时痰菌阴转率分别为50.00%(45/90)、66.67%(60/90)和83.33%(75/90),显著高于单纯化疗组(31.11%,28/90;40.00%,36/90;52.22%,47/90),差异有统计学意义(χ2值分别为6.660、12.857、19.943,P值均≤0.01);结核空洞超声电导组治疗有效率为40.00%(36/90)、50.00%(45/90)和83.33%(75/90),显著高于单纯化疗组(15.56%,14/90;31.11%,28/90;50.00%,45/90),两组差异有统计学意义(χ2值分别为 13.460、8.149、22.540,P值均<0.01);超声电导组与单纯化疗组不良反应发生率(分别为10.00%,9/90;14.44%,13/90),差异无统计学意义(χ2=0.829,P=0.363)。结论 超声电导经皮透药治疗复治空洞性肺结核可以提高患者的痰菌阴转率及空洞治疗有效率,是一种结核病治疗的新型给药途径。

关键词: 结核, 肺/药物疗法, 超声透入疗法, 评价研究

Abstract: Objective To explore the clinical effect of ultrasound-guided percutaneous conductance chemotherapy in the treatment of patients with cavity pulmonary tuberculosis (TB).  Methods One hundred and eighty smear and (or) culture positive retreatment pulmonary TB patients with cavity lesions who were diagnosed in Xi’an Tuberculosis and Thoracic Tumor Hospital from December 2011 to August 2012 were enrolled in this study. They were randomly divided into two anti-TB chemotherapy groups: oral administration combined with ultrasound-guided percutaneous conductance (study group, 92 cases) and oral administration only (control group, 91 cases). The treatment regimen for all patients in both groups was same (2HRZES/6HRE). The following indicators were observed and recorded respectively at 3 time-points (1 month, 3 months and 6 months of treatment): improvement of symptoms, sputum conversion rate, rate of lesion shrink, rate of cavity shrink, as well as appearance of complications and adverse reaction. Results In the study group, the sputum conversion rates were 50.00%(45/90), 66.67%(60/90) and 83.33%(75/90) respectively at the end of 1 month, 3 months and 6 month of treatment, which were significantly higher than those in the control group (31.11%, 28/90;40.00%,36/90 and 52.22%, 47/90; χ2=6.660, 12.857 and 19.943, P≤0.01). The effective rates of treatment (lesion and (or) cavity shrink) in the study group were 40.00%(36/90), 50.00%(45/90) and 83.33%(75/90) respectively at 3 time-points, which were significantly higher than those in the control group (15.56% (14/90), 31.11% (28/90) and 50.00% (45/90); χ2=13.460, 8.149 and 22.540, P<0.01). There was no significant difference in the complication and adverse reaction between study (10.00%, 9/90) and control groups (14.44%, 13/90) (χ2=0.829, P=0.363). Conclusion The sputum conversion rate of pulmonary TB patients can be improved by using chemotherapy combined with percutaneous ultrasound-guided conductivity. It is a safe, effective and new route of administration on TB treatment.

Key words: Tuberculosis, pulmonary/drug therapy, Phonophoresis, Evaluation study